Alkylating Agent Chemotherapy: — What to Expect

Nausea typically starts within hours of a dose and is usually managed with medicines given alongside your chemotherapy. Fatigue tends to build across the weeks of treatment rather than hitting immediately after the first cycle. Hair loss commonly begins within the first few weeks. Low blood counts reach their lowest point in the days following each cycle — your team will time blood tests around this. Side effects on fertility may only become apparent after treatment has ended, which is why the conversation about preservation needs to happen before your first dose.

It depends on the specific medicines you received, the total amount, your age at the time of treatment, and your baseline fertility beforehand. Alkylating agents can reduce or deplete egg and sperm reserves, and in some people that effect is permanent. The critical point is that fertility preservation — freezing eggs, sperm or embryos — must be arranged before your first dose, not after. If this has not been raised with you yet, ask at your next appointment. It is a reasonable and important question, and your oncologist can refer you to a fertility specialist if needed.

The increased risk is real and is recognised in ASCO and ESMO guidance, but it needs to be kept in proportion. The number of people who develop a second blood cancer after alkylating agent chemotherapy is small compared with the number who benefit from treating the original cancer. The risk also varies with the total amount received over your treatment course. What this means in practice is straightforward: tell any doctor you see in future — even years later, even in a different city — what chemotherapy you had, so they know what surveillance to consider. That is the action that matters.

For most people, yes. Hair loss with alkylating agents is usually temporary, and hair typically begins returning after treatment ends. The new growth may initially differ in texture or colour before settling back to your previous pattern. The extent of loss varies between different medicines in this class and between individuals — not every alkylating agent causes the same degree of thinning. For a small number of people, particularly after prolonged or high-dose treatment, some persistent thinning can occur. Ask your oncologist whether hair loss is expected with your specific regimen, since the answer differs by medicine.

Bone marrow suppression means your bone marrow is producing fewer blood cells than usual during treatment. This leads to three changes: fewer white cells, raising infection risk; fewer red cells, causing fatigue and breathlessness from anaemia; and fewer platelets, affecting how quickly blood clots. Your team will check blood counts regularly throughout your treatment. A fever during the low-count period is the most urgent symptom — it can mean your immune system does not have enough white cells to fight infection, and it needs same-day attention. Do not sleep on a fever during chemotherapy. Call the number your team has given you.

No, and this is worth understanding clearly. While the class shares a basic mechanism, medicines within it differ in how they are given, which organs they most affect, and what their main side effects are. Cisplatin is known particularly for kidney effects and nerve changes; carboplatin tends to cause more bone marrow suppression. Cyclophosphamide and ifosfamide are associated with bladder irritation. Temozolomide, taken as a capsule for brain tumours, has a different side-effect profile again. Chlorambucil and melphalan are used mainly in blood and bone marrow cancers. What your specific medicine causes is more relevant than the class in general — ask your oncologist or pharmacist to walk you through what to expect from your own regimen.